| CASE
A 54-year-old man was diagnosed with MPL mutated, primary myelofibrosis in 2004 with a hypercellular marrow, MF-2 fibrosis with megakaryocytic atypia, peripheral leukoerythroblastosis, splenomegaly, and an elevated lactate dehydrogenase. He was observed until 2010, when he was started on hydroxycarbamide for increasing symptoms. Prior to his 2011 enrollment in a clinical trial utilizing a novel JAK2 inhibitor, fedratinib, a bone marrow biopsy ( Figure 1 , Panel A; hematoxylin and eosin stain above, reticulin stain below, 10×) showed progressive megakaryocytic atypia and MF-3 fibrosis. Nearly 1 year into the trial, a repeat bone marrow ( Figure 1 constituents. Arrows show the iliac crests. A representative pseudocolor display that depicts 100% fat as dark red and 0% fat as dark blue is shown (Figure 2 , bottom row). The percent fat evident in the bone marrow imaging approximates that in the subcutaneous fat. After 3 bone marrow biopsies and the MR demonstrating this unusual transition of primary myelofibrosis to a fatty, aplastic appearing marrow, a repeat bone marrow in 2017 ( Figure 1 , Panel D; hematoxylin and eosin stain above, reticulin stain below, 20×) now showed a hypocellular marrow with histopathologic findings consistent with his marrow at the time of diagnosis. To our knowledge, this is the first case of a fibrotic marrow developing such an aplastic appearance in a patient treated with a JAK2 inhibitor.
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